TEMPLE, a Phase 3 multicenter, randomized, double-blind, head-to-head study, evaluated the tolerability, safety and efficacy of atogepant compared to topiramate for the preventive treatment of migraine in adult patients with a history of four or more migraine days per month
Pivotal phase III SUNMO study demonstrated an 11.5 month median progression-free survival - three times longer than R-GemOx
BRAVE study will explore the potential of omaveloxolone to address the critical unmet need of the pediatric FA population
QuantumNexis will serve as the innovative engine for HCTI's recurring revenue business lines
The company received seven observations in the Form-483
The GMP-compliant facility with automated environmental monitoring accommodates both white room and class 7 and 8 cleanroom space
SUP will obtain regulatory approvals for selling Tiotropium DPI in China
The company received one observation in the Form-483
The inspection concluded successfully, with the facility found to be in compliance with the required regulations
Innovative agents highlight growth of targeted protein degradation platform and BMS' leadership in innovative cancer therapies
Subscribe To Our Newsletter & Stay Updated
